Non-invasive fibrosis markers and α-fetoprotein (AFP) levels at 12 or 24 weeks after the end of treatment (SVR12 or 24) are reportedly associated with subsequent HCC development [8,9,10,11,12,13]. Here, AFP is linked to hepatocellular carcinoma.